A Detailed Analysis of the General Anesthesia Drugs Market: Poised for Robust Growth Driven by Increasing Surgical Procedures, Advancements in Drug Formulations, and Rising Healthcare Infrastructure Worldwide
Industry: Healthcare
Published Date: January-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 210
Report ID: PMRREP33865
The global General Anesthesia Drugs market is forecast to expand at a CAGR of 3.4% and thereby increase from a value of US$5.10 Bn in 2023 to US$6.44 Bn by the end of 2030.
|
Attributes |
Key Insights |
|
General Anesthesia Drugs Market Size (2023E) |
US$5.10 Bn |
|
Projected Market Value (2030F) |
US$6.44 Bn |
|
Global Market Growth Rate (CAGR 2023 to 2030) |
3.4% |
|
Historical Market Growth Rate (CAGR 2018 to 2022) |
3.3% |
|
Revenue Share of Top Four Countries (2022E) |
48% |
The general anesthesia drug is employed for inducing and sustaining a state of unconsciousness, ensuring the absence of pain sensation. This entails inducing unconsciousness, accompanied by a partial or complete loss of protective reflexes. Administered through intravenous or inhalation routes in combination with other medications, intravenous general anesthetic drugs include Propofol, Etomidate, and Ketamine, while inhalation anesthesia drugs include Sevoflurane and Desflurane. General anesthesia finds application in a spectrum of medical procedures, including cardiac surgeries, hip and knee replacements, cancer surgeries, and gastrointestinal surgeries.
The growth of the global market for general anesthesia drugs is primarily fueled by the escalating prevalence of chronic diseases such as cancer, cardiovascular disease, and osteoarthritis. The surge in demand for inhalation anesthesia, augmented funding from both private and government organizations for the development of pharmaceutical manufacturing segments, and increased research and development activities for formulating general anesthesia drugs also contribute significantly to market expansion. Furthermore, the World Health Organization's 2022 report highlights cardiovascular disease as the predominant cause of global mortality. Patients with conditions like coronary heart disease, heart failure, and atrial fibrillation, who are more susceptible to open-heart surgery procedures, further drive the growth of the market. In essence, these factors collectively propel the expansion of the global market for general anesthesia drugs
Increasing Frequency Of Surgeries And The Continuous Approval Of New Anesthesia Drugs
The significant drivers behind the expansion of this market include the increasing frequency of surgeries and the continuous approval of new anesthesia drugs. According to data from the American Society of Plastic Surgeons, there was a 3% rise in the number of cosmetic surgical procedures, cosmetic minimally invasive procedures, and reconstructive procedures in the United States in 2020 compared to 2019, reaching 2.3 million, 13.2 million, and 6.8 million, respectively. This upward trend underscores the growing demand for anesthesia drugs, aligning with the escalating number of surgeries.
Additionally, a report from the National Center for Biotechnology Information (NCBI) in July 2020 titled 'Trauma of Major Surgery' reveals that a staggering 310 million major surgeries are performed globally each year. Similarly, a July 2021 article titled 'Incidence and Cumulative Risk of Major Surgery in Older Persons in the United States' indicates that in the United States, almost nine major surgeries are conducted annually for every 100 older persons. Over five years, more than 1 in 7 Medicare beneficiaries undergo a major surgery, totaling nearly 5 million unique older individuals. These findings highlight the substantial market potential driven by the consistent demand for anesthesia drugs in response to the growing volume of surgical procedures.
Disadvantages Associated With Side Effects
The utilization of general anesthesia drugs, or anesthetics, may give rise to adverse effects, including nausea, vomiting, sore throat, respiratory system irritation, and, to a certain extent, neurotoxicity that could impact brain development and lead to cognitive impairment. These potential side effects are anticipated to pose challenges to the growth of the global market for general anesthesia drugs. For instance, findings published in the World Journal of Clinical Cases in August 2022 by Jinmei Song et al reported hysterical somatic disorders in patients undergoing general anesthesia induced by a combination of propofol and lidocaine. The study highlighted increased hemodilution resulting from the infusion of crystalloid solutions, leading to alterations in plasma volume. Furthermore, the impact on hemodynamics was noted to cause perioperative complications, predominantly of a cardiopulmonary nature. Additionally, the use of general anesthetics was associated with kidney injury, affecting the excretion of anesthetic metabolites and potentially resulting in adverse renal outcomes.
General Anesthetic Risks In Pediatric Patients And Pregnant Women
The administration of pharmacologic agents, particularly general anesthetic drugs, in pediatric patients requires heightened caution. Infants and young children exhibit distinct responses to anesthetic drugs compared to adults, influenced by factors such as body composition, protein binding, body temperature, cardiac output distribution, and the functional maturity of the liver and kidneys. Numerous studies indicate that prolonged exposure to general anesthetics and sedative medications in pregnant and young animals, exceeding three hours, results in significant nerve cell death in the brain. Furthermore, anesthesia may contribute to decreased blood flow to the uterus, potentially leading to fetal distress or even mortality. Additionally, the use of anesthesia can induce respiratory depression, posing risks to both the mother and the fetus.
Adoption Of Ambulatory Anesthesia To Propose Great Promise
The adoption of ambulatory anesthesia stands as a noteworthy business opportunity, offering a means for patients to recover rapidly from the effects of general anesthesia drugs and facilitating earlier discharge from hospitals. This approach not only benefits patients but also provides substantial advantages to third-party payers, hospitals, and healthcare providers. Furthermore, an increase in the overall number of approvals for general anesthetic drugs is anticipated to contribute to market expansion. A case in point is the approval by the United States Food and Drug Administration in September 2020 for the Propofol injectable anesthetic emulsion, a combination of general anesthesia and sedative medicines administered before surgical procedures. Such approvals play a pivotal role in shaping the market landscape and can have positive implications for stakeholders in the healthcare and pharmaceutical sectors.
The General Anesthesia Drugs Market is anticipated to undergo substantial expansion and change. The effectiveness of general anesthesia in the twentieth century saw significant advancements due to the widespread adoption of tracheal intubation methods and the introduction of novel anesthetic drugs with enhanced properties. Continuous innovation in drug formulations and delivery methods has further elevated the safety and efficacy standards of general anesthesia. Moreover, the market is poised for growth with the development of specific targeted drugs, offering the potential for enhanced efficacy and safety. In this landscape, the emergence of new and improved drugs featuring shorter onset times and reduced side effects is gaining substantial traction. Remimazolam, a novel benzodiazepine with an ultra-short half-life, is a notable example. Functioning as an anesthetic by binding to the benzodiazepine binding site of the GABAA receptor, Remimazolam has demonstrated reliability and efficiency in surgical sedation through various investigations. Its official licensing for surgical sedation drugs in key regions such as the United States, China, and Europe positions it as a significant player in the market, reflecting the demand for advanced and effective anesthesia solutions.
Supply-side Dynamics
Several factors, including the Global aging population, Surge in Surgical Procedures, and Rising Chronic Diseases, all contribute to the dynamic and rapid expansion of the global General Anesthesia Drugs market. Baxter International Inc., AstraZeneca, AbbVie Inc., B. Braun Melsungen AG, Fresenius SE & Co. KgaA, and Pfizer are market leaders in Anesthesia Drugs. The countries of Germany, Japan, China, India, and the United States are significant producers of drugs. The growing incidence of cancer is expected to drive the expansion of the general anesthesia market in the United States, given the frequent utilization of general anesthesia in surgical procedures aimed at treating cancer. The shift in lifestyle patterns in India has resulted in a surge in the number of surgeries, which is anticipated to propel the growth of the general anesthesia drugs market. In September 2022, AIIMS Delhi analyzed the five-year increase in knee replacement surgeries in India.
Several corporations are allocating resources towards expanding their capacity to satisfy the increasing need for Anesthesia Drugs. It is anticipated that these expansions will substantially alter the dynamics of the market, resulting in heightened competition, reduced prices, and an influx of innovative products. It is anticipated that expanding capacity will exert a substantial influence on market dynamics, resulting in heightened competition, reduced prices, and an increased availability of innovative products.
Which Drug Class Are Expected to Benefit the Most from Revenue Generation?
Increasing Incidences Of Emergency Surgeries, And A Rising Number Of Surgical Procedures Worldwide
Propofol stands out as one of the most widely employed general anesthetics in surgical settings and serves as a sedative for critical care, including ICU patients, including those with COVID-19. Its versatile applications encompass initiating and maintaining procedural sedation, general anesthesia, and more. A notable development in June 2020 was the approval by the United States Food & Drug Administration for the use of Fresenius Propoven 2% emulsion, specifically for sedation maintenance in COVID-19 patients aged 16 and above requiring mechanical ventilation. Propofol's significance extends to its role in the induction and maintenance of anesthesia, as well as its application in managing refractory status epilepticus. This long-standing use spans various surgical procedures necessitating anesthesia. Key manufacturers of propofol injections include Neon Laboratories Limited, Bharat Serums and Vaccines Limited, and Fresenius Kabi, positioning these companies as key players in the production and distribution of this crucial pharmaceutical product. Such developments and the involvement of prominent manufacturers contribute to the dynamic landscape of the pharmaceutical business, particularly in the anesthesia and critical care sectors.
What Route of Administration Will Be Targeted the Most?
Highest Percent Share Attributed To Sensors Owing To Their Accuracy, Lower Postoperative Nausea And Vomiting Rates, And Reduced Risk Of Blood Clots
The Anesthesia Drugs market is predominantly led by Intravenous Drugs, owing to their numerous advantages. These include precise dose delivery, enhanced patient safety, and lower incidence rates of postoperative complications such as nausea, vomiting, urinary retention, and malignant hyperthermia—a rare but severe side effect of general anesthesia. Additionally, the use of intravenous drugs is associated with a diminished risk of blood clots and pulmonary emboli, further solidifying their position as a preferred choice in the market. These advantages contribute to the market dominance of intravenous drugs in the anesthesia pharmaceutical sector, aligning with the priorities of precision, safety, and reduced postoperative complications.
Which End Users to Be Focused on the Most Regarding Sales?
Hospitals To Widen Footprint Due To Increasing Hospitals And Government Spending On Healthcare
The hospital segment dominated the market, driven by the increasing number of hospitals and government initiatives allocating higher expenditures to enhance the healthcare industry. The expansion in this market segment can be primarily attributed to the substantial influx of patients in hospitals and the escalating volume of surgeries conducted within these medical facilities.
Why is Europe Emerging as a Dominating Region?
Rising Aging Population With Increasing Chronic Conditions to Fuel Growth for Easier Market Adoption
In response to the emergence of COVID-19, the United States experienced substantial shortages of crucial anesthesia drugs, notably dexmedetomidine, midazolam, propofol, and neuromuscular blocking agents. This situation has prompted several companies to enhance their production of anesthesia drugs. For instance, Hikma Pharmaceutical introduced a new product, "Propofol Injectable Emulsion," in May 2020, addressing the heightened demand in the United States. Moreover, the market's momentum is fueled by factors such as the escalating number of surgeries, a growing aging population with an increase in chronic conditions, and advancements in anesthesia technologies. As per data from the American Society of Plastic Surgeons (ASPS), in 2020, approximately 768,000 total cosmetic procedures were performed among individuals aged 10-29 years, and 6.1 million total cosmetic procedures were conducted in the age group of 40-54-year-olds. These statistics underscore a consistent rise in surgical procedures in the region, consequently driving the demand for anesthesia drugs. The application of anesthetics in general surgeries is anticipated to be a significant contributor to the market's growth
What Opportunities Lie in Asia Pacific for Manufacturers?
Surge In Cosmetic Procedures To Advance Growth
In China, as of 2018, a notable surge in cosmetic procedures, including facelifts, lip augmentations, and rhinoplasty, was observed alongside a shift in the demographic profile of patients. The average age of patients undergoing cosmetic surgery decreased, with individuals under the age of 28 accounting for approximately 12 million out of the total 22 million Chinese individuals who underwent such procedures in 2018. Teenagers constituted 8% of the total procedures performed. Simultaneously, there has been a steady increase in the prevalence of cardiovascular diseases (CVD) in China. According to a 2018 study published in the Journal of Geriatric Cardiology by Li-Yuan Ma, among the 290 million individuals affected by CVD, more than 2 in 5 fatalities in China are attributed to this condition. This mortality rate surpasses those associated with cancer or other diseases.
Prominent organizations, including Baxter International Inc., AstraZeneca, and AbbVie Inc., are at the vanguard of this sector, providing inventive solutions by capitalizing on their technological prowess and vast experience in the Anesthesia Drugs industry. With the increase in drug approvals, mid-sized to smaller companies are expanding their market footprint by introducing new ingredients at more affordable prices. Additionally, they establish collaborations with drug manufacturers to enhance their product portfolios and market reach.
To distinguish themselves in this highly competitive market, these businesses strive to differentiate their products. They achieve this by providing distinctive attributes, and new product releases to match consumer demand and increase their client base.
New Product Launch
In June 2023, Hikma Pharmaceuticals PLC launched Midazolam injection pouches, featuring 0.9% Sodium Chloride (NaCl) in dosages of 50mg/50mL and 100mg/100mL. The medication received approval for continuous intravenous infusion to provide sedation for ventilated and oxygen-deprived adults, pediatric patients, and infants as part of anesthesia or critical care therapy in the United States.
Market Impact: The approval of continuous intravenous infusion for a range of patient populations, including adults, children, and neonates, represents a medical breakthrough. This invention caters to a wider range of patients, which could expand the market's use and reach.
In February 2022, Sedana Medical AB unveiled the introduction of Sedaconda (isoflurane) in the German market. This product, having received European DCP approval in July 2021, has also obtained national approvals in 14 countries. The company has submitted additional applications for marketing approval in the same year, with expectations to secure national approvals in Italy, Poland, Switzerland, and the United Kingdom in 2022.
Market Impact: The market for general anesthesia medications now offers a wider variety of products due to the introduction of Sedaconda, which contains isoflurane as its active ingredient. Due to this variability, medical providers have additional alternatives and can customize anesthesia regimes to meet the needs and preferences of their patients.
|
Attribute |
Details |
|
Forecast Period |
2023 to 2030 |
|
Historical Data Available for |
2018 to 2022 |
|
Market Analysis |
US$ Million for Value |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon request |
By Drug Class:
By Route of Administration:
By End-User:
By Region:
To know more about delivery timeline for this report Contact Sales
The market is anticipated to grow at a CAGR of 3.4% during the projected period.
The General Anesthesia Drugs market was valued at USD 5,101.2 million in 2023.
The U.S. held the largest market share in 2023.
The prominent players in the market are Baxter International Inc., AstraZeneca, AbbVie Inc., B. Braun Melsungen AG, Fresenius SE & Co. KgaA, and Pfizer, among others.
The propofol segment is expected to grow at the fastest growth during the forecast period.
